2021 Refresher - Lung

The management of non-small cell lung cancer has undergone major transformation in the last three years driven by the increasing use of immunotherapy as well as local ablative therapies in advanced stage disease. Translation of these practices into community based setting is important as overall survival in lung cancer has dramatically improved with incorporation of improved treatment. This educational activity will help participants to better apply new treatment strategies so that patient outcomes can be enhanced.

Target Audience

The activity is designed to meet the interests of radiation oncologists, medical oncologists, physicists, therapists, dosimetrists and radiation oncology residents.

Learning Objectives

    Upon completion of this live activity, attendees should be able to: 

    • Apply the increasing role of radiotherapy in advanced stage lung cancer.
    • Distinguish the instances when radiotherapy for advanced stage disease is not indicated.
    Course summary
    Available credit: 
    • 1.50 Certificate of Attendance
      This activity was designated for 1.50 AMA PRA Category 1 Credit™.
    • 1.50 SA-CME

      The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

      The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.

    Course opens: 
    03/19/2021
    Course expires: 
    04/20/2021
    Cost:
    $0.00
    Rating: 
    0

    Russell Hales, MD is employed by Johns Hopkins University and has no financial interest.

    The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.

    All relevant relationships have been mitigated.

     

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

    ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

    Available Credit

    • 1.50 Certificate of Attendance
      This activity was designated for 1.50 AMA PRA Category 1 Credit™.
    • 1.50 SA-CME

      The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

      The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.

    Price

    Cost:
    $0.00
    Please login or register to take this course.

    Policies: 
        • No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
        • No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
        • ASTRO staff cannot make modifications to your submitted materials.
     

    Required Hardware/software

    One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.